Arcutis Biotherapeutics, Inc. Common Stock
ARQTArcutis Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing dermatology and inflammatory disease treatments. Founded to innovate within the skin disease space, it emphasizes targeted therapies for conditions such as psoriasis, atopic dermatitis, and other inflammatory skin disorders.
Company News
Arcutis Biotherapeutics has submitted a supplemental New Drug Application to the FDA for ZORYVE cream 0.3%, seeking approval to treat plaque psoriasis in children ages 2 to 5. If approved by the June 29, 2026 target date, it would be the first topical PDE4 inhibitor for this age group.
Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.
Arcutis Biotherapeutics' Zoryve cream 0.15% has been approved by the FDA for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged six years and older. The approval is based on positive data from two phase III studies, and the company plans to make the drug widely available by the end of July.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported its first-quarter financial results after the bell Tuesday. Here's a look at the highlights. The Details: Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, be...
The company released phase 3 trial results for an atopic dermatitis cream.
